Weight Regain Seen After Cessation of GLP-1 Receptor Agonists in Adults With Overweight, Obesity

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 5, 2026.

via HealthDay

THURSDAY, March 5, 2026 -- Adults with overweight or obesity regain much of their lost weight after cessation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to a review published online March 4 in eClinicalMedicine.

Brajan Budini, from the University of Cambridge in the United Kingdom, and colleagues characterized the trajectory of weight regain after GLP-1 RA cessation in a systematic review and meta-analysis of randomized controlled trials (RCTs), nonrandomized interventional studies, and observational studies reporting weight outcomes after cessation of GLP-1 RAs in adults with overweight or obesity. Forty-eight relevant studies were included.

The researchers found that after cessation of GLP-1 RAs, weight consistently rebounded. The nonlinear meta-regression included six RCTs with 3,236 participants and used a mixed-effect exponential recovery model with random effects applied to the rate constant. Sixty percent of the weight lost during treatment was regained one year postcessation. Weight trajectories were extrapolated beyond 52 weeks; weight regain was estimated to plateau at 75.3 percent of the weight lost on treatment. The rate constant was 0.0302 per week, corresponding to a 23.0-week half-life. A moderate risk for bias was seen in most studies.

"Our projections show that even though people regain most of the weight they have lost, they still maintain some of the weight loss, but what we currently don't know is if the same proportion of lean mass is recovered," Budini said in a statement. "If the regained weight is disproportionately fat, individuals may ultimately be worse off than before in their fat-to-lean mass ratio, which may have adverse consequences for their health."

Two authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-03-06 02:13

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords